HUTCHMED to Announce 2023 Half-Year Financial Results
26 Junho 2023 - 5:30AM
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13)
will be announcing its interim results for the six months ended
June 30, 2023 on Monday, July 31, 2023 at 7:00 am Eastern Daylight
Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong
Kong Time (HKT).
Analysts and investors are invited to join a
conference call and audio webcast presentation with Q&A,
conducted by HUTCHMED management.
The conference call and audio webcast will take
place at 8:00 am EDT / 1:00 pm BST / 8:00 pm HKT on Monday, July
31, 2023 and will be webcast live via the company website at
www.hutch-med.com/event/. The presentation will be available for
downloading before the conference call begins. Details of the
conference call dial-in will be provided in the financial results
announcement and on the company website. A replay will also be
available on the website shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an
innovative, commercial-stage, biopharmaceutical company. It is
committed to the discovery and global development and
commercialization of targeted therapies and immunotherapies for the
treatment of cancer and immunological diseases. It has
approximately 5,000 personnel across all its companies, at the
center of which is a team of about 1,800 in oncology/immunology.
Since inception it has focused on bringing cancer drug candidates
from in-house discovery to patients around the world, with its
first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch-med.com or follow us on
LinkedIn.
CONTACTS
Investor Enquiries |
|
Mark Lee, Senior Vice President |
+852 2121 8200 |
Annie Cheng, Vice President |
+1 (973) 306-4490 |
|
|
Media Enquiries |
|
Americas – Brad Miles,
Solebury Strategic Communications |
+1 (917) 570 7340 (Mobile) /
bmiles@soleburystrat.com |
Europe – Ben Atwell / Alex Shaw,
FTI Consulting |
+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile) /
HUTCHMED@fticonsulting.com |
Asia – Zhou Yi, Brunswick |
+852 9783 6894 (Mobile) /
HUTCHMED@brunswickgroup.com |
|
|
Nominated Advisor |
|
Atholl Tweedie / Freddy Crossley / Daphne Zhang,
Panmure Gordon |
+44 (20) 7886 2500 |
HUTCHMED China (NASDAQ:HCM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
HUTCHMED China (NASDAQ:HCM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024